Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $23.41 USD
Change Today -0.77 / -3.18%
Volume 82.3K
DRNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 12:21 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

dicerna pharmaceuticals inc (DRNA) Snapshot

Open
$24.18
Previous Close
$24.18
Day High
$24.85
Day Low
$23.40
52 Week High
03/17/15 - $27.33
52 Week Low
11/6/14 - $8.00
Market Cap
417.2M
Average Volume 10 Days
116.1K
EPS TTM
$-3.11
Shares Outstanding
17.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DICERNA PHARMACEUTICALS INC (DRNA)

Related News

No related news articles were found.

dicerna pharmaceuticals inc (DRNA) Related Businessweek News

No Related Businessweek News Found

dicerna pharmaceuticals inc (DRNA) Details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver. It is also developing DCR-MYC, which is in Phase I clinical study for the treatment of various cancers in patients with solid tumors, multiple myeloma, or lymphoma, as well as in Phase Ib/II clinical trial to treat cancer in patients with advanced hepatocellular carcinoma. In addition, the company is developing KRAS oncogene, a gene that is mutated in various cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer; and a therapeutic targeting a second cancer-related gene. It has a license agreement with City of Hope, an academic research and medical center to manufacture, use, offer for sale, sell, and import products related to DsiRNA for the prevention and treatment of various diseases in humans; licensing and collaboration agreement with Tekmira Pharmaceuticals Corporation to license LNP delivery technology for use in PH1 development program; and a license agreement with Plant Bioscience Limited to research, discover, develop, manufacture, sell, import, and export products incorporating short RNA molecules. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

42 Employees
Last Reported Date: 03/12/15
Founded in 2006

dicerna pharmaceuticals inc (DRNA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $430.0K
Chief Financial Officer
Total Annual Compensation: $65.4K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $335.0K
Chief Medical Officer
Total Annual Compensation: $269.1K
Chief Business Officer
Total Annual Compensation: $295.0K
Compensation as of Fiscal Year 2014.

dicerna pharmaceuticals inc (DRNA) Key Developments

Dicerna Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Dicerna Pharmaceuticals Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the period, the reported loss from operations was $14,617,000 compared to $6,437,000 a year ago. Net loss was $14,590,000 compared to $6,719,000 a year ago. Net loss attributable to common stockholders was $14,590,000 compared to $6,728,000 a year ago. Net loss per basic and diluted share allocable to common stockholders was $0.82 compared to $199.91 a year ago. Non-GAAP loss per basic and diluted share was $0.57 against $186.72 for the same period a year ago. Non-GAAP net loss was $10,077,000 against $6,284,000 for the same period a year ago. For the year, the company reported loss from operations was $45,101,000 compared to $17,378,000 a year ago. Net loss was $47,939,000 compared to $18,518,000 a year ago. Net loss attributable to common stockholders was $48,143,000 compared to $20,906,000 a year ago. Net loss per basic and diluted share allocable to common stockholders was $3.00 compared to $709.57 a year ago. Non-GAAP loss per basic and diluted share was $2.12 against $615.99 for the same period a year ago. Non-GAAP net loss was $34,143,000 against $18,149,000 for the same period a year ago.

Dicerna Eyes Acquisitions

Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA) is looking for acquisition opportunities. Dicerna has filed shelf registration process, Dicerna offer up to 2.5 million shares of common stock from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of the offering. Dicerna use the part of proceeds for costs and structure of potential acquisitions, collaborations or other transactions.

Dicerna Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 12, 2015

Dicerna Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRNA:US $23.41 USD -0.77

DRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DRNA.
View Industry Companies
 

Industry Analysis

DRNA

Industry Average

Valuation DRNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DICERNA PHARMACEUTICALS INC, please visit www.dicerna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.